As of 2024-12-15, the EV/EBITDA ratio of Mersana Therapeutics Inc (MRSN) is -2.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRSN's latest enterprise value is 212.18 mil USD. MRSN's TTM EBITDA according to its financial statements is -77.78 mil USD. Dividing these 2 quantities gives us the above MRSN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.9x | 14.8x |
| Forward P/E multiples | 15.0x - 15.5x | 15.2x |
| Fair Price | (9.01) - (9.33) | (9.04) |
| Upside | -519.2% - -533.8% | -520.6% |
| Date | EV/EBITDA |
| 2024-12-13 | -2.73 |
| 2024-12-12 | -2.97 |
| 2024-12-11 | -3.57 |
| 2024-12-10 | -3.25 |
| 2024-12-09 | -3.36 |
| 2024-12-06 | -3.33 |
| 2024-12-05 | -3.00 |
| 2024-12-04 | -2.92 |
| 2024-12-03 | -3.08 |
| 2024-12-02 | -2.97 |
| 2024-11-29 | -2.93 |
| 2024-11-27 | -2.79 |
| 2024-11-26 | -2.76 |
| 2024-11-25 | -2.49 |
| 2024-11-22 | -2.55 |
| 2024-11-21 | -2.46 |
| 2024-11-20 | -2.84 |
| 2024-11-19 | -2.84 |
| 2024-11-18 | -2.66 |
| 2024-11-15 | -2.82 |
| 2024-11-14 | -3.32 |
| 2024-11-13 | -3.49 |
| 2024-11-12 | -2.81 |
| 2024-11-11 | -3.33 |
| 2024-11-08 | -3.40 |
| 2024-11-07 | -3.36 |
| 2024-11-06 | -3.03 |
| 2024-11-05 | -2.51 |
| 2024-11-04 | -2.24 |
| 2024-11-01 | -2.20 |
| 2024-10-31 | -2.19 |
| 2024-10-30 | -2.28 |
| 2024-10-29 | -2.39 |
| 2024-10-28 | -2.55 |
| 2024-10-25 | -2.33 |
| 2024-10-24 | -2.51 |
| 2024-10-23 | -2.59 |
| 2024-10-22 | -2.57 |
| 2024-10-21 | -2.65 |
| 2024-10-18 | -2.65 |
| 2024-10-17 | -2.66 |
| 2024-10-16 | -2.66 |
| 2024-10-15 | -2.70 |
| 2024-10-14 | -2.59 |
| 2024-10-11 | -2.44 |
| 2024-10-10 | -2.33 |
| 2024-10-09 | -2.30 |
| 2024-10-08 | -2.47 |
| 2024-10-07 | -2.43 |
| 2024-10-04 | -2.68 |